Smart insulin pump shows promise for type 2 diabetes control
NCT ID NCT05815342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the Omnipod 5, a wearable device that automatically delivers insulin, in 343 adults with type 2 diabetes. Participants used the system for 13 weeks to see if it improved blood sugar levels. The goal was to make diabetes management simpler and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Omnipod 5 Automated Insulin Delivery System (a device that automatically delivers insulin)
What this could lead to
If successful, this device could make managing type 2 diabetes easier and more effective by automating insulin delivery, reducing the need for manual injections and fingerstick checks.
What could go wrong
This was a single-arm study without a comparison group, so results may not be definitive. The device is not a cure and requires ongoing use. Some users may experience skin reactions or device malfunctions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AccellaCare
Wilmington, North Carolina, 28401, United States
-
Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
-
Diabetes and Glandular Disease Clinic
San Antonio, Texas, 78229, United States
-
Diabetes and Thyroid Center
Fort Worth, Texas, 76132, United States
-
East Coast Institute for Research
Jacksonville, Florida, 32216, United States
-
East Coast Institute for Research
Canton, Georgia, 30114, United States
-
Emory
Atlanta, Georgia, 30303, United States
-
Endocrine Research
Roswell, Georgia, 30076, United States
-
Health Partners
Minneapolis, Minnesota, 55416, United States
-
Henry Ford
Detroit, Michigan, 48202, United States
-
Joslin Diabetes
Boston, Massachusetts, 02215, United States
-
MAHEC
Asheville, North Carolina, 28803, United States
-
Metabolic Research Institute
West Palm Beach, Florida, 33401, United States
-
Ohio State
Columbus, Ohio, 43203, United States
-
Physicians East
Greenville, North Carolina, 27834, United States
-
Sansum Diabetes Research Institute
Santa Barbara, California, 93105, United States
-
Texas Diabetes and Endocrinology
Austin, Texas, 78731, United States
-
University Diabetes and Endocrine Consultants
Chattanooga, Tennessee, 37411, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
-
University of Southern California
Los Angeles, California, 90022, United States